Home/Pipeline/Telomelysin (OBP-301)

Telomelysin (OBP-301)

Various Cancers

Clinical DevelopmentActive

Key Facts

Indication

Various Cancers

Phase

Clinical Development

Status

Active

Company

Japanese biotech developing oncolytic adenovirus therapies and cancer diagnostics across multiple pipeline programs.

Drug	Company	Phase	Status
Oncology/Immuno-oncology Portfolio	MSD	Phase III/Commercial	Active
Bevacizumab Biosimilar	Dr. Reddy's Laboratories	Approved	Launched in UK
LADR Platform	LadRx	Preclinical	Research
NK Cell Stimulation (via JadiCell)	Therapeutic Solutions International	Preclinical	Research
Zip-Code Library for Oncology	Kodikaz Therapeutic Solutions	Pre-clinical	Active
Proprietary RLT Pipeline	Affibody	Not Specified (Preclinical-Phase 2)	Active
Preclinical ASO Portfolio	Isarna Therapeutics	Preclinical	Active
SPACE-GM Microenvironment Analysis	Enable Medicine	Research	Active
Oncology Program(s)	CIS Pharma	Pre-clinical	Active
Max Access Solutions (with The Max Foundation)	Tanner Pharma Group	N/A (Donation/Distribution Program)	Active
CPA Platform in Oncology	InnoSIGN	Development	Active
Oncology Services	Transcure Bioservices	Preclinical	Active